We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mitochondrial Protein Mediates Immune Response

By Biotechdaily staff writers
Posted on 13 Sep 2005
A novel mitochondrial membrane protein has been found to play a critical role in the immune system's response to viral infection.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) called the newly identified protein MAVS (mitochondrial antiviral signaling). The protein was found to span the mitochondrial membrane so that it is in contact with both the cell cytoplasm and the mitochondrial genetic material.

Previous studies had shown that viral infection triggered the activation of several transcription factors including NF-kappaB and IRF3. These factors prompt the cell to manufacture interferon, which is a potent antiviral agent. In the current work, published in the August 25, 2005, online edition of Cell, the investigators stopped MAVS production by using RNA interference to silence its gene. Cells in this condition could not activate NF-kappaB and IRF3, and viral replication was stimulated. However, in cells where there was overexpression of MAVS, heightened activity of NF-kappaB and IRF3 enhanced the production of beta-interferon and inhibited viral replication.

"This is the first mitochondrial protein known to be involved in immune defense against any microbial infection,” said senior author Dr. Zhijian Chen, associate professor of molecular biology at the University of Texas Southwestern Medical Center. "Viruses have evolved along with humans and have developed strategies to evade the host's immunity. It is quite possible that some viruses may target MAVS in order to achieve successful infection. In those cases, therapies that enhance MAVS expression or activity may be a viable option for boosting immune responses against viral diseases.”





Related Links:
U. Texas Southwestern Medical Center

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Automatic CLIA Analyzer
Shine i6000

Latest BioResearch News

Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
13 Sep 2005  |   BioResearch

Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
13 Sep 2005  |   BioResearch

Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
13 Sep 2005  |   BioResearch